Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Three-Year Lull, Alcon Cited For Professional Ad Violations

This article was originally published in The Pink Sheet Daily

Executive Summary

DDMAC has sent five letters since 2003 for violations in promotional materials directed at health care professionals.

You may also be interested in...

‘Tis The Season… For An FDA Enforcement Letter To Alcon

The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.

Rebate Card For Alcon’s Pataday Is More Than Meets The Eye, FDA Says

Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.

Allergan Promo For Acular LS Broadens Indications, FDA Warning Letter Says

Journal ad for the ophthalmic misleadingly suggests the drug is indicated for phacoemulsification, according to FDA.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts